Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding
- PMID: 22613904
- DOI: 10.1038/ajg.2012.132
Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding
Abstract
Objectives: To evaluate the effect of Helicobacter pylori (H. pylori) eradication on ulcer bleeding recurrence in a prospective, long-term study including 1,000 patients.
Methods: Patients with peptic ulcer bleeding were prospectively included. Prior non-steroidal anti-inflammatory drug (NSAID) use was not considered exclusion criteria. H. pylori infection was confirmed by rapid urease test, histology, or (13)C-urea breath test. Several eradication therapies were used. Subsequently, ranitidine 150 mg o.d. was administered until eradication was confirmed by (13)C-urea breath test 8 weeks after completing therapy. Patients with therapy failure received a second, third, or fourth course of eradication therapy. Patients with eradication success did not receive maintenance anti-ulcer therapy and were controlled yearly with a repeat breath test. NSAID use was not permitted during follow-up.
Results: Thousand patients were followed up for at least 12 months, with a total of 3,253 patient-years of follow-up. Mean age 56 years, 75% males, 41% previous NSAID users. In all, 69% had duodenal ulcer, 27% gastric ulcer, and 4% pyloric ulcer. Recurrence of bleeding was demonstrated in three patients at 1 year (which occurred after NSAID use in two cases, and after H. pylori reinfection in another one), and in two more patients at 2 years (one after NSAID use and another after H. pylori reinfection). The cumulative incidence of rebleeding was 0.5% (95% confidence interval, 0.16-1.16%), and the incidence rate of rebleeding was 0.15% (0.05-0.36%) per patient-year of follow up.
Conclusion: Peptic ulcer rebleeding virtually does not occur in patients with complicated ulcers after H. pylori eradication. Maintenance anti-ulcer (antisecretory) therapy is not necessary if eradication is achieved. However, NSAID intake or H. pylori reinfection may exceptionally cause rebleeding in H. pylori-eradicated patients.
Similar articles
-
Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding.Helicobacter. 2007 Aug;12(4):279-86. doi: 10.1111/j.1523-5378.2007.00490.x. Helicobacter. 2007. PMID: 17669099 Clinical Trial.
-
[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence].Med Clin (Barc). 1999 Feb 13;112(5):161-5. Med Clin (Barc). 1999. PMID: 10091208 Clinical Trial. Spanish.
-
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.Arch Intern Med. 2003 Sep 22;163(17):2020-4. doi: 10.1001/archinte.163.17.2020. Arch Intern Med. 2003. PMID: 14504114 Clinical Trial.
-
Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer.Aliment Pharmacol Ther. 2004 Mar 15;19(6):617-29. doi: 10.1111/j.1365-2036.2004.01898.x. Aliment Pharmacol Ther. 2004. PMID: 15023164 Review.
-
H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.Cochrane Database Syst Rev. 2003;(4):CD004062. doi: 10.1002/14651858.CD004062. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2004;(2):CD004062. doi: 10.1002/14651858.CD004062.pub2. PMID: 14584003 Updated. Review.
Cited by
-
Immunobiological effects of lipopolysaccharide derived from Helicobacter pylori and influence of a proton pump inhibitor lansoprazole on human polymorphonuclear leukocytes.Folia Microbiol (Praha). 2024 Dec;69(6):1369-1378. doi: 10.1007/s12223-024-01188-7. Epub 2024 Aug 17. Folia Microbiol (Praha). 2024. PMID: 39153156 Free PMC article.
-
Real-World Bleeding Risk of Anticoagulant and Nonsteroidal Anti-inflammatory Drugs Combotherapy versus Anticoagulant Monotherapy.Gut Liver. 2024 Sep 15;18(5):824-833. doi: 10.5009/gnl230541. Epub 2024 May 10. Gut Liver. 2024. PMID: 38726558 Free PMC article.
-
Focusing on Helicobacter pylori infection in the elderly.Front Cell Infect Microbiol. 2023 Mar 10;13:1121947. doi: 10.3389/fcimb.2023.1121947. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36968116 Free PMC article. Review.
-
Prophylactic transcatheter arterial embolization reduces rebleeding in non-variceal upper gastrointestinal bleeding: A meta-analysis.World J Gastroenterol. 2021 Oct 28;27(40):6985-6999. doi: 10.3748/wjg.v27.i40.6985. World J Gastroenterol. 2021. PMID: 34790019 Free PMC article.
-
Dealing with uncertainty in the treatment of Helicobacter pylori.Ther Adv Chronic Dis. 2018 Apr;9(4):93-102. doi: 10.1177/2040622318758240. Epub 2018 Feb 12. Ther Adv Chronic Dis. 2018. PMID: 29623181 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
